Published in N Engl J Med on September 14, 2000
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med (2009) 4.59
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood (2008) 3.52
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A (2009) 2.56
Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood (2011) 1.90
Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci U S A (2002) 1.70
Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest (2008) 1.58
Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother (2003) 1.55
Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol Blood Marrow Transplant (2007) 1.31
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A (2001) 1.30
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood (2008) 1.28
Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma. Br J Cancer (2011) 1.25
Musculoskeletal tissue engineering with human umbilical cord mesenchymal stromal cells. Regen Med (2011) 1.21
Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther (2013) 1.12
Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Immunotherapy (2009) 1.07
Stem cells in clinical practice: applications and warnings. J Exp Clin Cancer Res (2011) 1.06
Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity. J Clin Invest (2007) 1.06
Radiobiological basis of low-dose irradiation in prevention and therapy of cancer. Dose Response (2006) 1.05
Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2010) 1.03
Immunotherapy for renal cell carcinoma. Clin Dev Immunol (2011) 1.02
Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves beta(2)-integrin-mediated interaction. Neoplasia (2009) 0.98
The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. J Exp Med (2002) 0.96
Site-specific mutations in the mature form of human IL-18 with enhanced biological activity and decreased neutralization by IL-18 binding protein. Proc Natl Acad Sci U S A (2001) 0.96
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood (2008) 0.95
Adult neural stem cells: response to stroke injury and potential for therapeutic applications. Curr Stem Cell Res Ther (2011) 0.95
Strategy escalation: an emerging paradigm for safe clinical development of T cell gene therapies. J Transl Med (2010) 0.95
Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells. Br J Cancer (2011) 0.91
The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol Blood Marrow Transplant (2008) 0.89
Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Semin Immunopathol (2004) 0.89
Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. J Cancer Res Clin Oncol (2005) 0.89
Low dose total body irradiation followed by allogeneic lymphocyte infusion for refractory hematologic malignancy--an updated review. Leuk Lymphoma (2004) 0.88
Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors. Front Oncol (2013) 0.88
Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. World J Urol (2005) 0.86
Specific factors influence the success of autologous and allogeneic hematopoietic stem cell transplantation. Oxid Med Cell Longev (2010) 0.86
Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer. Oncogene (2011) 0.85
Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2007) 0.85
Immunotherapy of cancer: from vision to standard clinical practice. J Cancer Res Clin Oncol (2004) 0.85
Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer (2008) 0.85
Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? J Cancer (2011) 0.84
Adoptive immunotherapy against allogeneic kidney grafts in dogs with stable hematopoietic trichimerism. Biol Blood Marrow Transplant (2008) 0.84
Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. Br J Cancer (2010) 0.84
Science, medicine, and the future: Cellular immunotherapy for cancer. BMJ (2001) 0.84
Orchestrating an immune response against cancer with engineered immune cells expressing αβTCRs, CARs, and innate immune receptors: an immunological and regulatory challenge. Cancer Immunol Immunother (2015) 0.84
IPM chemotherapy in cytokine refractory renal cell cancer. Br J Cancer (2003) 0.84
The triterpenoid CDDO-Me delays murine acute graft-versus-host disease with the preservation of graft-versus-tumor effects after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant (2010) 0.83
Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells. World J Urol (2005) 0.83
Allogeneic stem cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol (2004) 0.83
Immunotherapy of cancer with alloreactive lymphocytes. N Engl J Med (2000) 0.82
A polymorphism in the splice donor site of ZNF419 results in the novel renal cell carcinoma-associated minor histocompatibility antigen ZAPHIR. PLoS One (2011) 0.82
Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment. Br J Cancer (2013) 0.82
Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation. J Immunol (2009) 0.82
Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation. Korean J Intern Med (2009) 0.81
Cord Blood Transplantation: Can We Make it Better? Front Oncol (2013) 0.81
In vitro-induced response patterns of antileukemic T cells: characterization by spectratyping and immunophenotyping. Clin Exp Med (2012) 0.81
Allogeneic hematopoietic cell transplantation: from experimental biology to clinical care. J Cancer Res Clin Oncol (2004) 0.80
Non-myeloablative allogeneic hematopoietic stem cell transplantation. Semin Oncol Nurs (2009) 0.80
Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives. J Clin Immunol (2002) 0.80
Cellular immune therapy for refractory cancers: novel therapeutic strategies. Exp Hematol (2005) 0.80
Low-intensity transplant regimens facilitate recruitment of donor-specific regulatory T cells that promote hematopoietic engraftment. Proc Natl Acad Sci U S A (2007) 0.80
Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens. Cancer Immunol Immunother (2010) 0.80
Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo. Oncotarget (2016) 0.79
Immune response to sipuleucel-T in prostate cancer. Cancers (Basel) (2012) 0.79
Immunologic mechanisms in RCC and allogeneic renal transplant rejection. Nat Rev Urol (2010) 0.79
High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses. Clin Cancer Res (2015) 0.78
Graft-versus-tumor effect after reduced-intensity allogeneic hematopoietic stem cell transplantation in a patient with advanced colon cancer. Int J Clin Oncol (2008) 0.78
Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens. Oncotarget (2016) 0.77
Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity. Oncoimmunology (2016) 0.77
Telomerase-pulsed dendritic cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Ger Med Sci (2006) 0.77
Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation. J Clin Immunol (2002) 0.77
Evidence for a graft-versus-tumor effect in refractory ovarian cancer. J Cancer Res Clin Oncol (2003) 0.77
Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma. ESMO Open (2016) 0.77
Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after. Expert Opin Biol Ther (2011) 0.77
Stem-cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol (2004) 0.77
Modification of heparanase gene expression in response to conditioning and LPS treatment: strong correlation to rs4693608 SNP. J Leukoc Biol (2013) 0.77
Recent advances of biomaterials in biotherapy. Regen Biomater (2016) 0.76
Evolving immunotherapeutic strategies in bladder and renal cancer. Postgrad Med J (2004) 0.76
Durable remission of renal cell carcinoma in conjuncture with graft versus host disease following allogeneic stem cell transplantation and donor lymphocyte infusion: rule or exception? PLoS One (2014) 0.76
Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumors. Cytotechnology (2003) 0.76
Full response of a localized renal tumour after reduced-intensity conditioned hematopoietic stem cell transplantation. Case Rep Med (2009) 0.76
Immune competence of cancer-reactive T cells generated de novo in adult tumor-bearing mice. Blood (2006) 0.76
Stem cells: An overview with respect to cardiovascular and renal disease. J Nat Sci Biol Med (2010) 0.76
Is allogeneic transplant for solid tumors still alive? Bone Marrow Transplant (2016) 0.75
Present and future perspectives on immunotherapy for advanced renal cell carcinoma: Going to the core or beating around the bush? J Kidney Cancer VHL (2015) 0.75
Prognostic relevance of extensive necrosis in renal cell carcinoma. J Clin Pathol (2005) 0.75
Trends in cancer immunotherapy. Clin Med Insights Oncol (2010) 0.75
Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation. Bone Marrow Transplant (2010) 0.75
Safety and Efficacy of Transplantation with Allogeneic Skin Tumors to Treat Chemically-Induced Skin Tumors in Mice. Med Sci Monit (2016) 0.75
Review of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in solid tumors excluding breast cancer. World J Transplant (2016) 0.75
Stem cell Transplantation for Eradication of Minimal PAncreatic Cancer persisting after surgical Excision (STEM PACE Trial, ISRCTN47877138): study protocol for a phase II study. BMC Cancer (2014) 0.75
Stem cells for all seasons? Experimental and clinical issues. J R Soc Med (2002) 0.75
Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC). J Cancer (2011) 0.75
Nonmyeloablative allogeneic stem cell transplantation for nasopharyngeal carcinoma. Oncologist (2010) 0.75
The importance of histology and cytogenetics in decision making for renal cell carcinoma. World J Urol (2008) 0.75
Nonmyeloablative allogeneic stem cell transplantation in metastatic renal cell carcinoma: a new therapeutic option or just a clinical experiment? World J Urol (2005) 0.75
Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta (1986) 13.69
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res (1982) 7.12
Cathepsin B, Cathepsin H, and cathepsin L. Methods Enzymol (1981) 6.84
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J (1973) 5.99
Evolutionary families of peptidases. Biochem J (1993) 5.81
L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J (1982) 5.67
Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med (1994) 4.86
Inhibition of transcription elongation by the VHL tumor suppressor protein. Science (1995) 4.23
Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science (1993) 4.12
Human cathepsin B1. Purification and some properties of the enzyme. Biochem J (1973) 4.06
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A (1996) 3.88
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A (1997) 3.75
The electrophoretically 'slow' and 'fast' forms of the alpha 2-macroglobulin molecule. Biochem J (1979) 3.58
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg (1989) 3.58
Evolutionary families of metallopeptidases. Methods Enzymol (1995) 3.48
5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med (1982) 3.29
Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A (1997) 3.27
A rapid and reproducible assay for collagenase using [1-14C]acetylated collagen. Anal Biochem (1979) 3.17
Cathepsin D. Purification of isoenzymes from human and chicken liver. Biochem J (1970) 3.09
A human parvovirus-like virus inhibits haematopoietic colony formation in vitro. Nature (1983) 3.02
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med (2005) 3.01
Families of serine peptidases. Methods Enzymol (1994) 2.94
Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med (1987) 2.93
A new assay for cathepsin B1 and other thiol proteinases. Anal Biochem (1972) 2.93
Small (< or = 3-cm) renal masses: detection with CT versus US and pathologic correlation. Radiology (1996) 2.90
Gram-negative sepsis: detection of endotoxemia with the limulus test. With studies of associated changes in blood coagulation, serum lipids, and complement. Ann Intern Med (1972) 2.79
BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet (2008) 2.79
Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med (2001) 2.75
High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet (2000) 2.75
Platelet alpha-granule proteins: studies on release and subcellular localization. Blood (1979) 2.74
Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet (2001) 2.68
Cathepsin B1. A lysosomal enzyme that degrades native collagen. Biochem J (1974) 2.65
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta (1996) 2.64
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat (1998) 2.64
An invertebrate coagulation system activated by endotoxin: evidence for enzymatic mediation. J Clin Invest (1972) 2.61
Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med (1996) 2.61
Cathepsin D. Characteristics of immunoinhibition and the confirmation of a role in cartilage breakdown. Biochem J (1971) 2.60
MEROPS: the peptidase database. Nucleic Acids Res (1999) 2.60
A microdissection technique for archival DNA analysis of specific cell populations in lesions < 1 mm in size. Am J Pathol (1995) 2.59
Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc Natl Acad Sci U S A (1991) 2.55
The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res (2001) 2.51
Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet (1998) 2.50
Cyclosporin A for the treatment of graft-versus-host disease in man. Lancet (1979) 2.48
The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet (1996) 2.45
Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med (2001) 2.45
An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature (1998) 2.44
Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood (2000) 2.42
Cystatin, a protein inhibitor of cysteine proteinases. Improved purification from egg white, characterization, and detection in chicken serum. Biochem J (1983) 2.42
von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology (1995) 2.38
Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci U S A (1985) 2.33
Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene (1997) 2.32
Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. Br J Haematol (2005) 2.32
Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology (1996) 2.26
Pectic polysaccharides of growing plant tissues. Biochem J (1967) 2.24
Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet (1981) 2.22
Fluorimetric assays for cathepsin B and cathepsin H with methylcoumarylamide substrates. Biochem J (1980) 2.20
Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med (1999) 2.17
Neutral proteinases of human spleen. Purification and criteria for homogeneity of elastase and cathepsin G. Biochem J (1976) 2.17
Human liver cathepsin L. Biochem J (1985) 2.16
Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med (1992) 2.12
Lysosomal acid proteinase of rabbit liver. Biochem J (1967) 2.12
The interaction of alpha2-macroglobulin with proteinases. Binding and inhibition of mammalian collagenases and other metal proteinases. Biochem J (1974) 2.11
Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood (2001) 2.11
Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest (1989) 2.08
The inhibition of tissue acid proteinases by pepstatin. Biochem J (1972) 2.06
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res (2001) 2.05
Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J Biol Chem (1986) 2.03
Allogeneic blood stem cell transplantation: considerations for donors. Blood (1997) 2.03
CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Arch Biochem Biophys (1992) 2.03
Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol (1989) 2.00
Hepatitis-associated aplastic anemia. N Engl J Med (1997) 1.98
Families of cysteine peptidases. Methods Enzymol (1994) 1.98
Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet (1988) 1.97
Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glycoprotein. Virology (1996) 1.97
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol (1999) 1.97
von Recklinghausen's disease and pheochromocytomas. J Urol (1999) 1.92
Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood (1995) 1.91
Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab (2001) 1.91
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst (1993) 1.91
Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood (2001) 1.89
Hypertension and convulsions in children receiving cyclosporin A. Lancet (1982) 1.89
Human cathepsin H. Biochem J (1980) 1.88
An improved color reagent for use in Barrett's assay of Cathepsin B. Anal Biochem (1976) 1.87
Hereditary papillary renal cell carcinoma. J Urol (1994) 1.87
Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet (2005) 1.85
Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med (1989) 1.85
Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res (1995) 1.85
Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol (1999) 1.84